DGX Dec 2024 150.000 call
| Previous close | 6.90 |
| Open | 6.90 |
| Bid | 5.70 |
| Ask | 7.50 |
| Strike | 150.00 |
| Expiry date | 2024-12-20 |
| Day's range | 6.90 - 6.90 |
| Contract range | N/A |
| Volume | |
| Open interest | 65 |
PR NewswireBlood-based MRD Test for Cancer Recurrence Can Generate Cost Savings in Colorectal Cancer Treatment, Finds Study in JAMA Health Forum
A blood test could help reduce costs for health plans by reliably identifying patients who might be able to safely forgo chemotherapy after surgery for stage II colorectal cancer, according to a study published today in JAMA Health Forum, a member of the JAMA Network. Researchers from Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company and developer of the Haystack MRD™ tumor-informed ctDNA MRD technology, City of Hope and the Walter and Eliza Hall Institute of Medical Research conducted
ZacksWhy Is Amedisys (AMED) Up 5.5% Since Last Earnings Report?
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ZacksWhy Is Quest Diagnostics (DGX) Up 3.1% Since Last Earnings Report?
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
